Leukemia, Lymphocytic, Chronic, B-Cell (4)

Lymphoma (1)

Lymphoma, Non-Hodgkin (1)

Lymphoma, Small Lymphocytic (1)

Recruiting (2)

Active, not recruiting (1)

Completed (1)

phase 1 (2)

phase 1/phase 2 (1)

phase 2 (1)

Bristol-Myers Squibb (1)

Genzyme, a Sanofi Company (1)

Janssen Research & Development, LLC (1)

Juno Therapeutics, a Subsidiary of Celgene (1)

alemtuzumab plus fludarabine (1)

bms-986403 (1)

cyclophosphamide (1)

fludarabine (1)

jcar017 (lisocabtagene maraleucel) (1)

jcar017 (lisocabtagene maraleucel) + ibrutinib (1)

jcar017 (lisocabtagene maraleucel) + venetoclax (1)

jnj-75348780 (1)

drug (3)

biological (1)

Industry (4)

Interventional (4)

Leukemia, Lymphocytic, Chronic, B-Cell

Showing NaN - NaN of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS